fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Levonorgestrel

All products: general benefit

Mirena · DIN 02243005 · 52 mg · Insert

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Mirena · DIN 02243005 Manufacturer: Bayer Inc., Consumer Care Division; listing date 2001-10-11 Health Canada: Marketed since 2007-11-22 · brand MIRENA · ATC G02BA03 PLASTIC IUD WITH PROGESTOGENS · form Insert (extended-release) · route Intrauterine · ingredients LEVONORGESTREL 52 MG · company Bayer inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mirena: Formulary list price $380.00 per unit (the source does not state the unit; exact figure $380.0000). What the ministry pays, not the patient.

Ministry pays: $380.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02243005)

Source record
DIN 02243005: Mirena Raw flags: sec3=Y Item: 681200003; group id 729; item number 1793; lccId None; manufacturer id BAY Source form: Insert; strength: 52mg Recorded listing: General benefit Source prices (unrounded): $380.0000; ministry $380.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243005 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66845
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243005
Shortage record checked October 6, 2026

Other products in the same Health Canada class (G02B): coverage varies; not interchangeable

  • Ethinyl estradiol + etonogestrel (Nuvaring): not a benefit
Other drugs in the same formulary class (68:12 Contraceptives) and how they are covered

Matched class: 68:12 Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ETONOGESTREL 68:12 Contraceptives

ETHINYL ESTRADIOL & ETONOGESTREL

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.120mg & 0.015mg/24 hr · Slow Release Vag Ring

ETONOGESTREL

· 1 products · General benefit · strengths: 68mg/Implant · ER Subdermal Implant

NORETHINDRONE ACETATE/ETHINYL ESTRADIOL & ETHINYL ESTRADIOL

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg/10mcg & 10mcg · Tab-28 Tab Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:12
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications MIRENA (levonorgestrel-releasing intrauterine system) is indicated for: • conception control for maximum up to 8 years • treatment of idiopathic menorrhagia following appropriate diagnostic investigation for up to 5 years in individuals accepting the contraceptive effect of MIRENA 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics: MIRENA has not been studied in individuals over the age of 65 years. No data are available to Health Canada, therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00081240.PDF PM date: 2025-07-30 Source product: MIRENA; DIN 02243005; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.